基于过氧化物酶体增殖物激活受体探索治疗非酒精性脂肪肝的新视角  

Exploring a New Perspective on Treating Non-Alcoholic Fatty Liver Disease Based on Peroxisome Proliferator-Activated Receptor

作　　者：谭永娇 吴蓉[1] 

机构地区：[1]重庆医科大学附属第二医院消化内科,重庆

出　　处：《临床医学进展》2024年第4期2674-2684,共11页Advances in Clinical Medicine

摘　　要：非酒精性脂肪肝(Nonalcoholic fatty liver disease, NAFLD)涉及到脂代谢紊乱、炎症反应、纤维化、肝血管功能障碍等一系列复杂的病理生理过程。昼夜节律的不协调也在NAFLD的发展中扮演重要角色。过氧化物酶体增殖物激活受体(peroxisome proliferator-activated receptors, PPARs)作为核受体超家族的重要成员,包括PPARα、PPARβ/δ和PPARγ,在脂质代谢、炎症、肝星状细胞激活、维持正常血管功能以及昼夜节律等多个生理方面都发挥关键作用。PPARs参与调节NAFLD发病机制的多个方面。本文旨在从多个角度探讨PPARs作为潜在的NAFLD治疗靶点的可能性。Nonalcoholic fatty liver disease (NAFLD) involves a complex pathological process encompassing lipid metabolism disruption, inflammatory responses, fibrosis, and hepatic vascular dysfunction. The dysregulation of circadian rhythms also plays a significant role in NAFLD development. Peroxisome proliferator-activated receptors (PPARs), pivotal members of the nuclear receptor superfamily, including PPARα, PPARβ/δ, and PPARγ, play critical roles in multiple physiological aspects such as lipid metabolism, inflammation, hepatic stellate cell activation, maintenance of normal vascular function, and circadian rhythms. PPARs are involved in regulating various aspects of the pathogenesis of NAFLD. This paper aims to explore the potential of PPARs as therapeutic targets for NAFLD from multiple perspectives.

关 键 词：非酒精性脂肪肝 过氧化物酶体增殖物激活受体 肝脂肪变性 炎症反应 肝星状细胞 昼夜节律 微血管功能障碍 

分 类 号：R57[医药卫生—消化系统]